Edgewise Therapeutics (EWTX) Change in Accured Expenses (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Change in Accured Expenses data on file, last reported at $635000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 420.49% year-over-year to $635000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 70.27% YoY), and the FY2025 full-year result was $691000.0, down 40.33% from the prior year.
• Change in Accured Expenses fell to $635000.0 in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q2 2023 to a low of -$2.8 million in Q1 2024.
• A 5-year average of $316588.2 and a median of $635000.0 in 2026 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses sank 242.96% in 2022 and soared 420.49% in 2026, its largest moves.
• Tracing EWTX's Change in Accured Expenses over 5 years: stood at $1.3 million in 2022, then fell by 3.09% to $1.3 million in 2023, then decreased by 14.69% to $1.1 million in 2024, then surged by 30.78% to $1.4 million in 2025, then slumped by 55.78% to $635000.0 in 2026.
• Business Quant data shows EWTX's Change in Accured Expenses at $635000.0 in Q1 2026, $1.4 million in Q4 2025, and $548000.0 in Q3 2025.